The global infectious disease therapeutics market size was USD 119.37 billion in 2023, calculated at USD 123.91 billion in 2024 and is expected to reach around USD 179.91 billion by 2034, expanding at a CAGR of 3.8% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Infectious Disease Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Infectious Disease Therapeutics Market, by Mode of Treatment, 2024-2034
8.1.1. Vaccines
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Drugs
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Infectious Disease Therapeutics Market, by Target Organism e, 2024-2034
9.1.1. Antifungal
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Antiviral
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Antibacterial
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Anti-parasite
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Infectious Disease Therapeutics Market, by Infection Type, 2024-2034
10.1.1. Viral
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Parasitic
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Fungal
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Bacterial
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2021-2034)
11.1. Infectious Disease Therapeutics Market, by Distribution Channel, 2024-2034
11.1.1. Clinic
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Avastin
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Hospitals
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.1.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.1.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.2.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.2.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.3.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.3.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.4.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.4.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.5.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Mode of Treatment (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Target Organism (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.1. Pfizer Inc. (U.S.)
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. GlaxoSmithKline plc. (U.K)
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck & Co. (U.S.)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche Ltd (Switzerland)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca (U.K)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Mylan N.V. (U.S.)
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Novartis AG (Switzerland)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Sanofi (France)
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample